Patient profile
Age: 65 years
Sex: Male
Clinical History
- Long-standing chronic prostatitis
- Prior 12-core biopsy (2024)
- Persistent PSA elevation
Diagnosis (2025)
- Cancer type: Prostate cancer
- Histology: Acinar adenocarcinoma (conventional type)
- Diagnosis status: First confirmed diagnosis
- Risk category: Unfavorable Intermediate → Borderline High Risk
- PSA at diagnosis:
- 5.7 ng/mL (MRI)
- 5.25 ng/mL (PET-CT)
BLOOD MARKER EVOLUTION (29 Dec 2025 → 30 Jan 2026)
| Marker | Before | After | Interpretation |
|---|---|---|---|
| PSA (ng/mL) | 5.7 | 3.1 | –46% |
| CRP (mg/L) | 62 | 0.8 | –99% |
| CEA | 1.43 | 0.96 | Reduced |
| RBC | 4.88 | 4.98 | Stable |
| WBC | 8.91 | 7.9 | Normalized |
| Hemoglobin (g/dL) | 13.9 | 13.9 | Stable |
| Lymphocytes (abs) | 4.12 | 4.32 | Strong immune profile |
| Platelets | 329 | 323 | Stable |
| Iron | 33 | 110 | Repleted |
| Testosterone (ng/dL) | 538 | 844 | Androgen restoration |
| Estradiol (pg/mL) | 43.26 | 36.9 | Reduced estrogen excess |
| HbA1c (%) | 5.3 | 5.2 | Optimal |
| Glucose (mg/dL) | 82 | 89 | Normal |
| Vitamin D (ng/mL) | 86 | 104 | Optimal-high |
| Creatinine (mg/dL) | 0.64 | 0.65 | Normal |
| Spike Protein (U/mL) | 2376 | 2277 | Persistently elevated |
INTERPRETATION
1. PSA Reduction
- PSA dropped 5.7 → 3.1 ng/mL (–46%) within ~30 days
- This magnitude of decline strongly suggests reduced tumor activity and inflammatory contribution, particularly relevant in a background of chronic prostatitis.
2. Inflammation Collapse
- CRP fell 62 → 0.8 mg/L (–99%), indicating near-complete suppression of systemic and prostate-driven inflammation.
3. Hormonal Rebalancing
- Testosterone increased significantly while estradiol declined, improving the androgen-to-estrogen ratio, a key driver of prostate cancer biology.
4. Metabolic & Immune Stability
- Glycemic control remained optimal
- Strong lymphocyte count
- Improved iron status
- Preserved renal function
Residual Risk: Elevated Spike Protein
Despite marked improvements in PSA, inflammation, and hormonal balance, spike protein remains elevated (2376 → 2277 U/mL).
Persistently high spike protein is associated with endothelial inflammation, immune dysregulation, microclot formation, and pro-oncogenic signaling, which can sustain a low-grade inflammatory tumor environment and interfere with immune surveillance.
Planned Targeted Intervention
The next phase focuses on vascular and spike-related cleanup:
- Nattokinase — to support spike protein detox, microclot, and fibrin breakdown
- Nicotine — to potentially displace spike interaction at nicotinic acetylcholine receptors and reduce spike-mediated signaling
This step aims to further stabilize the inflammatory–vascular–immune axis, supporting continued disease control.
OVERALL ASSESSMENT
Within one month, this patient demonstrated:
- Rapid PSA reduction
- Near-total inflammation resolution
- Hormonal optimization
- Strong metabolic and immune stability
The remaining challenge is persistently elevated spike protein, which is now being directly addressed to further reduce oncogenic and inflammatory pressure.
Direction of change remains clearly favorable.
